演題抄録

ワークショップ

開催概要
開催回
第53回・2015年・京都
 

高齢者非小細胞肺癌に対するエルロチニブの有効性と安全性の検討 (LOGiK0802)

演題番号 : WS67-4

[筆頭演者]
末次 隆行:1,11 
[共同演者]
枝國 信貴:2,11、井上 孝治:3,11、内野 順治:4,11、西田 千夏:5,11、坂上 公太:1,11、近藤 晃:6,11、原田 大志:7,11、滎田 浩文:8,11、岸本 淳司:9,11、高山 浩一:7,11、千場 博:10,11

1:川内市医師会立市民病院呼吸器内科、2:久留米大学医学部内科学講座 呼吸器・神経・膠原病内科部門、3:北九州市立医療センター呼吸器内科、4:福岡大学医学部呼吸器内科、5:産業医科大学医学部呼吸器内科、6:JCHO諫早総合病院呼吸器内科、7:九州大学胸部疾患研究施設、8:日本赤十字社熊本赤十字病院呼吸器内科、9:九州大学次世代医療研究開発講座、10:社団法人熊本市医師会熊本地域医療センター呼吸器内科、11:九州肺癌研究機構

 

Purpose: The aim of this study is to evaluate the efficacy and safety of elrotinib treatment for aged patients with advanced non-small-cell lung cancer (NSCLC). Method: Advanced NSCLC patients who were 75 years old and previously treated within two regimens were administered with 150mg of elrotinib daily until disease progression or intolerable toxicities. Result: 40 patients were registered in this study. Patient demographics is as follows; median age 77, ranging from 75 to 84, 28 male patients, 17 patients with PS0, 33 patients with adenocarcinoma, 26 smokers, 10 patients with EGFR sensitive mutations. Overall response rate was 20.0% and disease control rate was 62.5%. Progression free survival was 151 days and overall survival was 372 days. Adverse events with grade 3 or 4 included 20% skin rash, 5% appetite loss and 2.5% diarrhea. The overall survival with EGFR sensitive mutations, 884 days was significantly longer than that patients with EGFR wild type or unknown. Conclusion: Erlotinib monotherapy was feasible and effective for the previously treated advanced NSCLC patients over 75 years old.

キーワード

臓器別:肺・縦隔・胸膜

手法別:臨床試験

前へ戻る